HLA and KIR polymorphisms affect NK-cell anti-tumor activity

Trends in Immunology

Volumn 28, Issue 10, 2007, Pages 437-441

  Passweg, Jakob R ^a   Huard, Bertrand ^a,b   Tiercy, Jean Marie ^a   Roosnek, Eddy ^a  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^b UNIVERSITY OF GENEVA MEDICAL SCHOOL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

HLA ANTIGEN; INTERLEUKIN 2; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR; LIGAND;

ACUTE GRANULOCYTIC LEUKEMIA; ADOPTIVE TRANSFER; ALLELE; ANTINEOPLASTIC ACTIVITY; ANTIVIRAL ACTIVITY; ARTICLE; AUTOIMMUNE DISEASE; CANCER IMMUNOTHERAPY; CANCER PATIENT; CELL ACTIVITY; CELL KILLING; CELLULAR IMMUNITY; GENE EXPRESSION; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC RISK; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HLA SYSTEM; HUMAN; IMMUNOLOGICAL TOLERANCE; LEUKEMIA CELL; NATURAL KILLER CELL; NONHUMAN;

AUTOIMMUNITY; CYTOTOXICITY, IMMUNOLOGIC; HLA ANTIGENS; HUMANS; IMMUNE TOLERANCE; IMMUNOTHERAPY; KILLER CELLS, NATURAL; LEUKEMIA, MYELOID, ACUTE; NEOPLASMS; POLYMORPHISM, GENETIC; RECEPTORS, KIR;

EID: 34548840534     PISSN: 14714906     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.it.2007.07.008     Document Type: Article

References (50)

1. Trinchieri G. Biology of natural killer cells. Adv. Immunol. 47 (1989) 187-376
2. Moretta A., et al. Activating receptors and coreceptors involved in human natural killer cell-mediated cytolysis. Annu. Rev. Immunol. 19 (2001) 197-223
3. Lanier L.L. NK cell recognition. Annu. Rev. Immunol. 23 (2004) 225-274
4. Bryceson Y.T., et al. Activation, coactivation, and costimulation of resting human natural killer cells. Immunol. Rev. 214 (2006) 73-91
5. Karre K., et al. Selective rejection of H-2-deficient lymphoma variants suggests alternative immune defence strategy. Nature 319 (1986) 675-678
6. Fernandez N.C., et al. A subset of natural killer cells achieve self-tolerance without expressing inhibitory receptors specific for self MHC molecules. Blood 105 (2005) 4416-4423
7. Kim S., et al. Licensing of natural killer cells by host major histocompatibility complex class I molecules. Nature 436 (2005) 709-713
8. Anfossi N., et al. Human NK cell education by inhibitory receptors for MHC class I. Immunity 25 (2006) 331-342
9. Cooley S., et al. A subpopulation of human peripheral blood NK cells that lacks inhibitory receptors for self MHC is developmentally immature. Blood 110 (2007) 578-586
10. Bordignon C., et al. Cell therapy: achievements and perspectives. Haematologica 84 (1999) 1110-1149
11. Lowdell M.W., et al. The in vitro detection of anti-leukaemia-specific cytotoxicity after autologous bone marrow transplantation for acute leukaemia. Bone Marrow Transplant. 19 (1997) 891-897
12. Vitale A., et al. Cytotoxic effectors activated by low-dose IL-2 plus IL-12 lyse IL-2-resistant autologous acute myeloid leukaemia blasts. Br. J. Haematol. 101 (1998) 150-157
13. Siegler U., et al. Activated natural killer cells from patients with acute myeloid leukemia are cytotoxic against autologous leukemic blasts in NOD/SCID mice. Leukemia 19 (2005) 2215-2222
14. Lauria F., et al. In vitro susceptibility of acute leukemia cells to the cytotoxic activity of allogeneic and autologous lymphokine activated killer (LAK) effectors: correlation with the rate and duration of complete remission and with survival. Leukemia 8 (1994) 724-728
15. Lowdell M.W., et al. Evidence that continued remission in patients treated for acute leukaemia is dependent upon autologous natural killer cells. Br. J. Haematol. 117 (2002) 821-827
16. Meloni G., et al. Interleukin-2 may induce prolonged remissions in advanced acute myelogenous leukemia. Blood 84 (1994) 2158-2163
17. Goodman M., et al. Interleukin-2 and leukemia. Leukemia 12 (1998) 1671-1675
18. Parham P. MHC class I molecules and KIRs in human history, health and survival. Nat. Rev. Immunol. 5 (2005) 201-214
19. Khakoo S.I., and Carrington M. KIR and disease: a model system or system of models?. Immunol. Rev. 214 (2006) 186-201
20. Hiby S.E., et al. Combinations of maternal KIR and fetal HLA-C genes influence the risk of preeclampsia and reproductive success. J. Exp. Med. 200 (2004) 957-965
21. Yawata M., et al. Roles for HLA and KIR polymorphisms in natural killer cell repertoire selection and modulation of effector function. J. Exp. Med. 203 (2006) 633-645
22. Leung W., et al. Comparison of killer Ig-like receptor genotyping and phenotyping for selection of allogeneic blood stem cell donors. J. Immunol. 174 (2005) 6540-6545
23. Carrington, M. and Norman, P. (2003) The KIR Gene Cluster, National Library of Medicine (US), NCBI (http://www.ncbi.nlm.nih.gov/books/bookres.fcgi/mono_003/ch1d1.pdf)
24. Valiante N.M., et al. Functionally and structurally distinct NK cell receptor repertoires in the peripheral blood of two human donors. Immunity 7 (1997) 739-751
25. O'Connor G.M., et al. Functional polymorphism of the KIR3DL1/S1 receptor on human NK cells. J. Immunol. 178 (2007) 235-241
26. Yen J.H., et al. Major histocompatibility complex class I-recognizing receptors are disease risk genes in rheumatoid arthritis. J. Exp. Med. 193 (2001) 1159-1167
27. Martin M.P., et al. Epistatic interaction between KIR3DS1 and HLA-B delays the progression to AIDS. Nat. Genet. 31 (2002) 429-434
28. van der Slik A.R., et al. KIR in type 1 diabetes: disparate distribution of activating and inhibitory natural killer cell receptors in patients versus HLA-matched control subjects. Diabetes 52 (2003) 2639-2642
29. Khakoo S.I., et al. HLA and NK cell inhibitory receptor genes in resolving hepatitis C virus infection. Science 305 (2004) 872-874
30. Momot T., et al. Association of killer cell immunoglobulin-like receptors with scleroderma. Arthritis Rheum. 50 (2004) 1561-1565
31. Nelson G.W., et al. Cutting edge: heterozygote advantage in autoimmune disease: hierarchy of protection/susceptibility conferred by HLA and killer Ig-like receptor combinations in psoriatic arthritis. J. Immunol. 173 (2004) 4273-4276
32. Cook M., et al. Donor KIR genotype has a major influence on the rate of cytomegalovirus reactivation following T-cell replete stem cell transplantation. Blood 107 (2006) 1230-1232
33. Carr W.H., et al. KIR3DL1 polymorphisms that affect NK cell inhibition by HLA-Bw4 ligand. J. Immunol. 175 (2005) 5222-5229
34. Thananchai H., et al. Cutting edge: allele-specific and peptide-dependent interactions between KIR3DL1 and HLA-A and HLA-B. J. Immunol. 178 (2007) 33-37
35. Tay C.H., et al. NK cell response to viral infections in β2-microglobulin-deficient mice. J. Immunol. 154 (1995) 780-789
36. Grau R., et al. Cytotoxic activity of natural killer cells lacking killer-inhibitory receptors for self-HLA class I molecules against autologous hematopoietic stem cells in healthy individuals. Exp. Mol. Pathol. 76 (2004) 90-98
37. Carrington M., et al. Hierarchy of resistance to cervical neoplasia mediated by combinations of killer immunoglobulin-like receptor and human leukocyte antigen loci. J. Exp. Med. 201 (2005) 1069-1075
38. Ruggeri L., et al. Role of natural killer cell alloreactivity in HLA-mismatched hematopoietic stem cell transplantation. Blood 94 (1999) 333-339
39. Ruggeri L., et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 295 (2002) 2097-2100
40. Leung W., et al. Determinants of antileukemia effects of allogeneic NK cells. J. Immunol. 172 (2004) 644-650
41. Hsu K.C., et al. Improved outcome in HLA-identical sibling hematopoietic stem cell transplantation for acute myelogenous leukemia (AML) predicted by KIR and HLA genotypes. Blood 105 (2005) 4878-4884
42. Miller J.S., et al. Missing KIR-ligands is associated with less relapse and increased graft versus host disease (GVHD) following unrelated donor allogeneic HCT. Blood 109 (2007) 5058-5061
43. Sobecks R.M., et al. Survival of AML patients receiving HLA-matched sibling donor allogeneic bone marrow transplantation correlates with HLA-Cw ligand groups for killer immunoglobulin-like receptors. Bone Marrow Transplant. 39 (2007) 417-424
44. Ruggeri L., et al. Donor natural killer cell allorecognition of missing self in haploidentical hematopoietic transplantation for acute myeloid leukemia: challenging its predictive value. Blood 110 (2007) 433-440
45. Miller J.S., et al. Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood 105 (2005) 3051-3057
46. Ciccone E., et al. Evidence of a natural killer (NK) cell repertoire for (allo) antigen recognition: definition of five distinct NK-determined allospecificities in humans. J. Exp. Med. 175 (1992) 709-718
47. Lanier L.L. The role of natural killer cells in transplantation. Curr. Opin. Immunol. 7 (1995) 626-631
48. Bignon J.D., and Gagne K. KIR matching in hematopoietic stem cell transplantation. Curr. Opin. Immunol. 17 (2005) 553-559
49. Witt C.S., and Christiansen F.T. The relevance of natural killer cell human leucocyte antigen epitopes and killer cell immunoglobulin-like receptors in bone marrow transplantation. Vox Sang. 90 (2006) 10-20
50. Herberman R.B., et al. Natural cytotoxic reactivity of mouse lymphoid cells against syngeneic and allogeneic tumors. II. Characterization of effector cells. Int. J. Cancer 16 (1975) 230-239